Key Insights

Highlights

Success Rate

72% trial completion

Published Results

13 trials with published results (15%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

15.5%

13 terminated out of 84 trials

Success Rate

72.3%

-14.2% vs benchmark

Late-Stage Pipeline

4%

3 trials in Phase 3/4

Results Transparency

38%

13 of 34 completed with results

Key Signals

13 with results72% success13 terminated

Data Visualizations

Phase Distribution

73Total
Not Applicable (30)
Early P 1 (4)
P 1 (19)
P 2 (17)
P 3 (3)

Trial Status

Completed34
Active Not Recruiting17
Terminated13
Recruiting11
Withdrawn7
Not Yet Recruiting1

Trial Success Rate

72.3%

Benchmark: 86.6%

Based on 34 completed trials

Clinical Trials (84)

Showing 20 of 20 trials
NCT07391774Phase 3Recruiting

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

NCT03939481Active Not Recruiting

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

NCT01334021Phase 2Active Not Recruiting

Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer

NCT04993313Not ApplicableActive Not Recruiting

Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study

NCT04090567Phase 2Recruiting

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

NCT04266249Phase 2Active Not Recruiting

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

NCT04001829Phase 2Active Not Recruiting

Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

NCT04816006Not ApplicableRecruiting

Breast Cancer, Reasoning, and Activity Intervention

NCT04754412Not ApplicableActive Not Recruiting

Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stage 0-III Breast Cancer Survivors, Writing to Heal Study

NCT05269381Phase 1Recruiting

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

NCT05025059Not ApplicableActive Not Recruiting

Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer

NCT05812807Phase 3Recruiting

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

NCT07259304Active Not Recruiting

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

NCT05455658Phase 2Active Not Recruiting

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

NCT05092373Phase 1Recruiting

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

NCT06538389Phase 2Suspended

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

NCT04216472Phase 2Terminated

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

NCT07331077Not ApplicableNot Yet Recruiting

A Physical Activity Program Compared to Health Education for Improving Memory and Attention in Hispanic Women With Newly-Diagnosed Stage I-IIIa Breast Cancer, MAMA Trial

NCT05368428Not ApplicableTerminated

Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer

NCT05319873Phase 1Active Not Recruiting

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Scroll to load more

Research Network

Activity Timeline